Teza Capital Management LLC Sells 71,252 Shares of Edwards Lifesciences Corporation $EW

Key Points

• Teza Capital Management LLC significantly reduced its holdings in Edwards Lifesciences by selling 71,252 shares, bringing its ownership down to 19,584 shares which is valued at approximately $1,419,000.
• Various hedge funds have modified their positions in Edwards Lifesciences, with Nuveen LLC acquiring $330.9 million in new shares and Jennison Associates LLC increasing its stake by 34.3% during the first quarter.
• Edwards Lifesciences reported a quarterly EPS of $0.67, exceeding expectations, while the stock has a current average target price of $85.90 with a rating of "Moderate Buy" from analysts.

Teza Capital Management LLC trimmed its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 78.4% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,584 shares of the medical research company's stock after selling 71,252 shares during the quarter. Edwards Lifesciences accounts for 0.6% of Teza Capital Management LLC's holdings, making the stock its 21st biggest holding. Teza Capital Management LLC's holdings in Edwards Lifesciences were worth $1,419,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in EW. Brighton Jones LLC acquired a new position in Edwards Lifesciences in the 4th quarter valued at $266,000. Bank Pictet & Cie Europe AG grew its holdings in Edwards Lifesciences by 16.7% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 10,231 shares of the medical research company's stock valued at $757,000 after buying an additional 1,463 shares in the last quarter. Cary Street Partners Financial LLC acquired a new position in Edwards Lifesciences in the 4th quarter valued at $495,000. Captrust Financial Advisors grew its holdings in Edwards Lifesciences by 11.8% in the 4th quarter. Captrust Financial Advisors now owns 49,703 shares of the medical research company's stock valued at $3,680,000 after buying an additional 5,248 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its holdings in Edwards Lifesciences by 70.0% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 75,911 shares of the medical research company's stock valued at $5,620,000 after buying an additional 31,264 shares in the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Trading Down 1.7%

Edwards Lifesciences stock traded down $1.37 during trading hours on Friday, hitting $76.65. The stock had a trading volume of 1,876,474 shares, compared to its average volume of 4,421,672. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The stock has a market cap of $45.00 billion, a price-to-earnings ratio of 11.04, a P/E/G ratio of 3.78 and a beta of 1.07. Edwards Lifesciences Corporation has a one year low of $64.00 and a one year high of $83.00. The business's 50 day simple moving average is $78.91 and its 200-day simple moving average is $75.35.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.62 by $0.05. The firm had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business's quarterly revenue was up 11.9% on a year-over-year basis. During the same period last year, the company earned $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, equities analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 4,114 shares of the company's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the sale, the vice president directly owned 22,002 shares in the company, valued at $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider directly owned 206,900 shares of the company's stock, valued at $16,150,614. This represents a 4.15% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 22,014 shares of company stock worth $1,698,844 in the last quarter. Corporate insiders own 1.29% of the company's stock.

Analyst Ratings Changes

A number of research analysts have commented on the company. Daiwa America raised Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, July 29th. Mizuho increased their target price on Edwards Lifesciences from $87.00 to $95.00 and gave the stock an "outperform" rating in a report on Friday, July 25th. Barclays increased their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the stock an "overweight" rating in a report on Friday, July 25th. The Goldman Sachs Group reissued a "buy" rating on shares of Edwards Lifesciences in a report on Friday, July 25th. Finally, Wells Fargo & Company increased their target price on Edwards Lifesciences from $84.00 to $88.00 and gave the stock an "overweight" rating in a report on Thursday, August 7th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Edwards Lifesciences currently has an average rating of "Moderate Buy" and a consensus price target of $86.26.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.